Xarelto(Rivaroxaban)
JNJ
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Johnson & Johnson
$6.23B
Medicare cost, 2024
$6.23B
Medicare cost, 2024
Medicare drug plans spent $6.2 billion on Xarelto (rivaroxaban) in 2024, for 6.7 million prescriptions and refills filled by 1.3 million patients. It ranks 5th among all drugs by Medicare drug plan spending. California accounts for the most spending ($495.2 million, 8% of the total). It is made by Johnson & Johnson (JNJ).
Medicare cost, 2024
$6.23B
-1.2% from 2023
Prescriptions
6.7M
$935.73 per claim
Patients
1.3M
348,034 prescribers
Total spending, 2024
$6.23B
$4,717.75 per patient
Questions and answers
How much does Medicare spend on Xarelto?
Medicare prescription drug plans paid $6.23B for Xarelto in 2024, for 6,658,485 prescriptions and refills to 1,320,644 patients (down 1.2% from 2023). The average cost per claim was $935.73.
Which state spends the most on Xarelto?
California had the highest Medicare cost for Xarelto in 2024: $495.2M for 511,553 claims, followed by Florida ($475.3M).
Who prescribes Xarelto the most?
Cindy S Kennedy, pharmacist in Charlotte, NC, had the highest Medicare cost for Xarelto in 2024: 1,585 claims costing $2.5M.
Who makes Xarelto?
Xarelto is made by Johnson & Johnson (JNJ), listed in the Medicare spending data as Janssen Pharm..
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Xarelto was $6.23B in 2024, after a high of $6.31B in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Xarelto, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Cindy S Kennedy Charlotte, NC | Pharmacist | 1,585 | 473 | $2.5M |
| Huong K Ha Sepulveda, CA | Pharmacist | 1,856 | 660 | $2.4M |
| Prakash D Shah Milwaukee, WI | Cardiology | 1,950 | 478 | $2.4M |
| Jennifer L Tresser Martinez, CA | Pharmacist | 1,680 | 633 | $2.3M |
| Mayer Rashtian Pasadena, CA | Clinical Cardiac Electrophysiology | 1,800 | 462 | $2.1M |
| David H Lau New York, NY | Cardiology | 2,571 | 419 | $2.0M |
| Carmen Wong Union City, CA | Pharmacist | 1,387 | 496 | $1.7M |
| Jordan Wong San Francisco, CA | Pharmacist | 1,318 | 449 | $1.7M |
| Yili Huang Elmhurst, NY | Cardiology | 1,603 | 405 | $1.5M |
| Cres P Miranda Jr. Las Vegas, NV | Cardiology | 1,138 | 343 | $1.4M |
| Hyeon Hye Lee Cupertino, CA | Pharmacist | 992 | 370 | $1.3M |
| William H Skinner Lexington, KY | Cardiology | 1,173 | 269 | $1.3M |
| Ajay Tuli Tucson, AZ | Interventional Cardiology | 975 | 268 | $1.3M |
| Michael C Liou New York, NY | Interventional Cardiology | 1,537 | 269 | $1.3M |
| David H Hoch Roslyn, NY | Clinical Cardiac Electrophysiology | 969 | 304 | $1.2M |
| Cash Casey Elmhurst, IL | Clinical Cardiac Electrophysiology | 1,032 | 240 | $1.2M |
| Hossein Amirani Wichita, KS | Cardiology | 1,261 | 248 | $1.2M |
| Harry R Hawthorne Alexandria, LA | Clinical Cardiac Electrophysiology | 1,472 | 288 | $1.2M |
| Maria R Peluso Winston Salem, NC | Pharmacist | 754 | 262 | $1.2M |
| Lynne Hung Mission Viejo, CA | Clinical Cardiac Electrophysiology | 1,119 | 285 | $1.2M |
| Avichai Eres Lexington, KY | Cardiology | 968 | 254 | $1.2M |
| Mauricio Melhado West Palm Beach, FL | Cardiology | 1,473 | 305 | $1.2M |
| Dharmesh S Patel Southaven, MS | Cardiology | 1,243 | 319 | $1.2M |
| Paul E Bejarano Tucson, AZ | Cardiology | 822 | 229 | $1.1M |
| Ronald G Ryder Hamilton, NJ | Cardiology | 908 | 226 | $1.1M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 339,918 | 6,523,366 | 1,311,050 | $5.77B |
| 2023 | 343,437 | 6,651,363 | 1,323,475 | $6.31B |
| 2024 | 348,034 | 6,658,485 | 1,320,644 | $6.23B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Janssen Pharm. | 6,660,246 | $6.23B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 28
- RxNorm concept IDs
- 1114198, 1114202, 1232082, 1232084, 1232086
- Application numbers
- NDA022406, NDA215859
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 208,599 side-effect reports named rivaroxaban, the active ingredient of Xarelto (reports from 2007 on). 174,869 of them (83.8%) were serious, 27,259 named a death and 104,157 named a hospital stay. The reactions named most often were gastrointestinal haemorrhage, off label use and haemorrhage. 40,323 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
208,599
7,035 in 2025 (-15.4% from 2024)
Serious
83.8%
174,869 reports
Deaths named
27,259
13.1% of reports
Hospital stays
104,157
49.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Xarelto?
208,599 reports from 2007 through September 2026 named rivaroxaban, the active ingredient of Xarelto. 174,869 of them (83.8%) were serious, 27,259 named a death and 104,157 named a hospital stay.
What are the most reported side effects of Xarelto?
21,672 reports named gastrointestinal haemorrhage, the reaction named most often, followed by off label use (8,056) and haemorrhage (7,819). In the last 5 years the reaction named most often was off label use (2,352 reports). A report can name several reactions.
How many side-effect reports named Xarelto in 2025?
7,035 reports were received in 2025 (-15.4% from 2024). 2026 so far: 5,145 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Xarelto caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Xarelto caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
JNJ·JNJ drug pipeline - Drug approvals (2 approvals on file for rivaroxaban) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (rivaroxaban) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.